Snowden, John A. and Saccardi, Riccardo and Orchard, Kim and Ljungman, Per and Duarte, Rafael F. and Labopin, Myriam and McGrath, Eoin and Brook, Nigel and de Elvira, Carmen Ruiz and Gordon, Debra and Poirel, Helene A. and Ayuk, Francis and Beguin, Yves and Bonifazi, Francesca and Gratwohl, Alois and Milpied, Noel and Moore, John and Passweg, Jakob and Rizzo, J. Douglas and Spellman, Stephen R. and Sierra, Jorge and Solano, Carlos and Sanchez-Guijo, Fermin and Worel, Nina and Gusi, Andreu and Adams, Gillian and Balan, Theodor and Baldomero, Helen and Macq, Gilles and Marry, Evelyne and Mesnil, Florence and Oldani, Elena and Pearce, Rachel and Perry, Julia and Raus, Nicole and Schanz, Urs and Tran, Steven and Wilcox, Leonie and Basak, Grzegorz W. and Chabannon, Christian and Corbacioglu, Selim and Dolstra, Harry and Kuball, Jurgen and Mohty, Mohamad and Lankester, Arjan and Montoto, Sylvia and Nagler, Arnon and Styczynski, Jan and Yakoub-Agha, Ibrahim and de Latour, Regis Peffault and Kroeger, Nicolaus and Brand, Ronald and de Wreede, Liesbeth C. and van Zwet, Erik and Putter, Hein (2020) Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). BONE MARROW TRANSPLANTATION, 55 (4). pp. 681-694. ISSN 0268-3369, 1476-5365
Full text not available from this repository. (Request a copy)Abstract
In many healthcare settings, benchmarking for complex procedures has become a mandatory requirement by competent authorities, regulators, payers and patients to assure clinical performance, cost-effectiveness and safe care of patients. In several countries inside and outside Europe, benchmarking systems have been established for haematopoietic stem cell transplantation (HSCT), but access is not universal. As benchmarking is now integrated into the FACT-JACIE standards, the EBMT and JACIE established a Clinical Outcomes Group (COG) to develop and introduce a universal system accessible across EBMT members. Established systems from seven European countries (United Kingdom, Italy, Belgium, France, Germany, Spain, Switzerland), USA and Australia were appraised, revealing similarities in process, but wide variations in selection criteria and statistical methods. In tandem, the COG developed the first phase of a bespoke risk-adapted international benchmarking model for one-year survival following allogeneic and autologous HSCT based on current capabilities within the EBMT registry core dataset. Data completeness, which has a critical impact on validity of centre comparisons, is also assessed. Ongoing development will include further scientific validation of the model, incorporation of further variables (when appropriate) alongside implementation of systems for clinically meaningful interpretation and governance aiming to maximise acceptance to centres, clinicians, payers and patients across EBMT.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | CLINICAL-OUTCOMES; SURGERY; UNIT; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation |
| Depositing User: | Petra Gürster |
| Date Deposited: | 09 Apr 2021 05:35 |
| Last Modified: | 09 Apr 2021 05:35 |
| URI: | https://pred.uni-regensburg.de/id/eprint/44854 |
Actions (login required)
 |
View Item |
